A5072040286- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- interferon and immune responses
- Bacterial Infections and Vaccines
- T-cell and B-cell Immunology
- Bacteriophages and microbial interactions
- Melanoma and MAPK Pathways
- Streptococcal Infections and Treatments
- Redox biology and oxidative stress
- Nanoplatforms for cancer theranostics
- Pneumonia and Respiratory Infections
University of Duisburg-Essen
2022-2023
Deutschen Konsortium für Translationale Krebsforschung
2021-2022
German Cancer Research Center
2022
Düsseldorf University Hospital
2021
Heinrich Heine University Düsseldorf
2021
University of Trento
2018-2019
Bacterial outer membrane vesicles (OMVs) represent an interesting vaccine platform for their built-in adjuvanticity and simplicity of production process. Moreover, OMVs can be decorated with foreign antigens using different synthetic biology approaches. However, the optimal OMV engineering strategy, which should guarantee compartmentalization most heterologous in quantities high enough to elicit protective immune responses, remains validated. In this work we exploited lipoprotein transport...
Recent studies have demonstrated HLA class II (HLA-II)-dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution HLA-II-loss tumors that escape T-cell activity and contribute to immunotherapy resistance.Melanoma from longitudinal metastases were studied for constitutive IFN-inducible HLA-II expression, sensitivity towards autologous cells, immune evasion loss. Clinical significance HLA-II-low was determined analysis transcriptomic data sets patients with...
Drug-tolerant persister cells (DTPs) exhibit remarkable cell state heterogeneity and phenotypic evolvability. However, the central question of how DTPs epigenetically coordinate their metabolic flexibility to adapt early therapeutic stress remains unanswered. We have recently shown that histone demethylase KDM5B, which is intrinsically expressed in differentiated melanoma DTPs, reprograms landscape. exact mechanism by KDM5B affects underlying enzymes, whether this reveals new druggable...
Human FAT1 is overexpressed on the surface of most colorectal cancers (CRCs) and in particular a 25 amino acid sequence (D8) present one 34 cadherin extracellular repeats carries epitope recognized by mAb198.3, monoclonal antibody which partially protects mice from challenge with human CRC cell lines xenograft mouse models. Here we data immune competent demonstrating potential D8-FAT1 as cancer vaccine. We first demonstrated that homolog (mD8-FAT1) also expressed CT26 B16F10 murine lines....
Background Immune-stimulatory agents, like agonists of the innate immune receptor RIG-I, are currently tested in clinical trials as an intratumoral treatment option for patients with unresectable melanoma, aiming to enhance anti-tumor T cell responses. Switching melanoma toward a dedifferentiated state has recently been linked and therapy resistance. It remains be determined whether RIG-I affect differentiation, potentially leading Methods Patient metastases-derived lines were treated...
<div>AbstractPurpose:<p>Recent studies have demonstrated HLA class II (HLA-II)–dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution HLA-II–loss tumors that escape T-cell activity and contribute to immunotherapy resistance.</p>Experimental Design:<p>Melanoma from longitudinal metastases were studied for constitutive IFN-inducible HLA-II expression, sensitivity towards autologous cells, immune evasion loss. Clinical significance...
<p>JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells</p>
<p>ConstHLA-II melanoma cells lack endogenous interferon expression</p>
<p>Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61</p>
<p>HLA-II expression in longitudinal melanoma samples</p>
<p>HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients</p>
<div>Abstract<p>Purpose: Recent studies have demonstrated HLA class II (HLA-II)-dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution HLA-II-loss tumors that escape cell activity and contribute to immunotherapy resistance. Experimental Design: Melanoma from longitudinal metastases were studied for constitutive interferon-inducible HLA-II expression, sensitivity towards autologous cells, immune evasion loss. Clinical significance HLA-II-low was...
<p>Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61</p>
<p>ConstHLA-II melanoma cells lack endogenous interferon expression</p>
<p>No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells</p>
<p>JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells</p>
<p>HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients</p>
<p>HLA-II expression in longitudinal melanoma samples</p>
<p>CD4 T-cell sensitivity of constHLA-II melanoma cells</p>
<p>CD4 T-cell sensitivity of constHLA-II melanoma cells</p>
<p>No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells</p>
<div>Abstract<p>Purpose: Recent studies have demonstrated HLA class II (HLA-II)-dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution HLA-II-loss tumors that escape cell activity and contribute to immunotherapy resistance. Experimental Design: Melanoma from longitudinal metastases were studied for constitutive interferon-inducible HLA-II expression, sensitivity towards autologous cells, immune evasion loss. Clinical significance HLA-II-low was...
<p>Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61</p>
<p>No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells</p>